Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of chlorogenic acid in preparation of drug for treating choriocarcinoma

A technique for choriocarcinoma and chlorogenic acid, applied in the field of biomedicine

Inactive Publication Date: 2015-05-06
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF3 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been reported that chlorogenic acid has a variety of pharmacological effects, but there are few reports on the treatment of choriocarcinoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chlorogenic acid in preparation of drug for treating choriocarcinoma
  • Application of chlorogenic acid in preparation of drug for treating choriocarcinoma
  • Application of chlorogenic acid in preparation of drug for treating choriocarcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 Simulation experiment of anti-tumor effect of chlorogenic acid targeting CTLA-4

[0030] cell culture

[0031] The choriocarcinoma cell line JEG-3 was grown in high-glucose DMEM complete medium containing 10% fetal bovine serum (supplemented with 2mmol / L glutamine, 1mmol / L sodium pyruvate, 100U / ml penicillin and 100U / ml streptomycin In a 37°C, 5% CO2 incubator, the medium was changed every 3 or 3 days. When the cells are about 70% to 80% full, passage with 0.25% trypsin and 0.02% EDTA mixture at a ratio of 1:3.

[0032] MTT colorimetric assay for cell proliferation

[0033] Take the JEG-3 cells in the exponential growth phase according to the initial concentration of 3 × 10 4 / ml inoculated in 96-well plate, and divided into 6 groups: control group, IL-12 group, CTLA-4+IL-12 group, 0.01 μM chlorogenic acid+CTLA-4+IL-12 group, 0.1 μM chlorogenic acid +CTLA-4+IL-12 group and 1μM chlorogenic acid+CTLA-4+IL-12 group at 37°C, 5%CO 2 After culturing in the incu...

Embodiment 2

[0040] Effect of Example 2 on the proliferation of JEG-3 choriocarcinoma cells

[0041] cell culture

[0042] The choriocarcinoma cell line JEG-3 was grown in high-glucose DMEM complete medium containing 10% fetal bovine serum (supplemented with 2mmol / L glutamine, 1mmol / L sodium pyruvate, 100U / ml penicillin and 100U / ml streptomycin In a 37°C, 5% CO2 incubator, the medium was changed every 3 or 3 days. When the cells are about 70% to 80% full, passage with 0.25% trypsin and 0.02% EDTA mixture at a ratio of 1:3.

[0043] MTT colorimetric assay for cell proliferation

[0044] Take the JEG-3 cells in the exponential growth phase according to the initial concentration of 3 × 10 4 / ml inoculated in a 96-well plate, and divided into 5 groups: control group, IL-12 group, chlorogenic acid 0.01 μM, 0.1 μM, 1 μM group at 37 ° C, 5% CO 2 After culturing in the incubator for 48 hours, replace it with serum-free medium to continue starvation and synchronization for 24 hours; then add IL-1...

Embodiment 3

[0051] Example 3 Chlorogenic acid inhibits the activity of CTLA-4

[0052] The inhibitory mechanism of CTLA-4 is realized by mediating the apoptosis of activated T cells. The researchers found that CTLA-4 can mediate Fas-independent T cell apoptosis. After the apoptosis of activated T cells, the number of effector T cells decreases, the secretion of cytokines decreases, and the immune function of the body is naturally suppressed.

[0053] Mouse CTLA-4 model, BALB / c mouse, male, 18-22g. CTLA-430mg / kg dose was injected once, and the establishment of the model was evaluated 14 days later. The next day after the model was successfully established, the animals were randomly divided into groups, weighed, and began to administer drugs. Chlorogenic acid injection (a series of intraperitoneal injections of chlorogenic acid with different concentrations made by dissolving chlorogenic acid in normal saline according to the dosage) The administration volume is 0.2ml per 10g mouse intra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of chlorogenic acid in preparation of a drug for treating choriocarcinoma, and belongs to the field of biological medicine. The drug is prepared from chlorogenic acid as an active constituent and used for treating choriocarcinoma. The chlorogenic acid has the function of inhibiting tumors, meanwhile is harmless to a human body, and can improve the immunity of the organism, the organism hematopoietic function and the hepatorenal function; furthermore, the chlorogenic acid can block or reduce the inhibiting function of CTLA-4 on T cell immunological competence, so as to stimulate the immune cells to be proliferated in quantity, and further enhance the immunoreaction of the organism to the tumors; meanwhile, the drug can be combined with other anti-tumor drugs to play a more prominent anticancer effect on choriocarcinoma.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the use of chlorogenic acid in the preparation of medicines for treating choriocarcinoma. technical background [0002] Gestational trophoblastic tumor is caused by abnormal development and proliferation of gestational trophoblastic cells. It is a group of rare trophoblast tissue diseases. It can be regarded as an allograft originating from infiltration of maternal (afterbirth) tissue for conception. It has a unique morphology It mainly includes invasive hydatidiform mole, choriocarcinoma and placental site trophoblastic tumor, among which choriocarcinoma is extremely invasive and widely metastatic, and can metastasize to blood vessels at an early stage, endangering the life of the patient. Clinically, chemotherapy is mainly used, and surgery is used as a supplementary method for treatment, but there are still some high-risk metastatic patients with drug resistance and recu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61P35/00
CPCA61K31/216
Inventor 张洁殷蕊蕊黄骏黄望
Owner SICHUAN JIUZHANG BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com